NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday
06:03pm, Monday, 14'th Jun 2021
The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment.
SRNE Stock Price Increased 6.65%: Why It Happened
04:33pm, Monday, 14'th Jun 2021
The stock price of Sorrento Therapeutics Inc (NASDAQ: SRNE) increased by 6.65% today. This is why it happened.
SRNE Stock: The Big News Lifting Sorrento Therapeutics Today
03:47pm, Monday, 14'th Jun 2021
Today, SRNE stock is on the move in a big way as investors price in two key announcements made by the company regarding clinical trials. The post SRNE Stock: The Big News Lifting Sorrento Therapeutics
Sorrento, Mayo Clinic Ink Research Pact For Ipilimumab-Delivering Sofusa In Melanoma Patients
07:20am, Monday, 14'th Jun 2021
Sorrento Therapeutics Inc (NASDAQ: SRNE) entered into a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery
Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK
07:15am, Monday, 14'th Jun 2021
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 trial evaluating COVI-DROPS in newly diagnosed COVID-19 infected
3 Stocks Wall Street Expects Will Double or Triple in 1 Year
06:36am, Saturday, 12'th Jun 2021
If analysts are right, these stocks offer implied upside ranging from 105% to as much as 216%.
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA), the United King
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical proof
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), a license and
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
01:00pm, Friday, 04'th Jun 2021
SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional collaborat
Why Sorrento Therapeutics Stock Surged Today
04:54pm, Wednesday, 02'nd Jun 2021
The biotech could play an important role in the battle against cancer and autoimmune diseases.
Biotech Stock Surges on Covid Test Approval
10:14am, Wednesday, 02'nd Jun 2021
The shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) are up 6.1% to trade at $8.10 at last check, after news that the company has initiated the start of its Covid-19 test roll-out in Mexico.
7 Former Pandemic Stocks to Buy That Are No Longer Running Hot
10:07am, Wednesday, 26'th May 2021
The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable.
Sorrento Reports Encouraging Data From Sofusa-Administered Enbrel In Rheumatoid Arthritis
09:48am, Thursday, 20'th May 2021
Sorrento Therapeutics Inc (NASDAQ: SRNE) reported positive initial results from the Phase 1B study of its Sofusa Lymphatic Delivery System administering Amgen Inc's (NASDAQ: AMGN) Enbrel for rhe
SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed wit
